These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23318251)

  • 1. Design principles for innovative workspaces to increase efficiency in pharmaceutical R&D: lessons learned from the Novartis campus.
    Zoller FA; Boutellier R
    Drug Discov Today; 2013 Apr; 18(7-8):318-22. PubMed ID: 23318251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Who talks to whom about what? How interdisciplinary communication and knowledge of expertise distribution improve in integrated R&D labs.
    Heinzen M; Cacciatori E; Zoller FA; Boutellier R
    Ergonomics; 2018 Aug; 61(8):1139-1153. PubMed ID: 29508648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new application of value-stream mapping in new drug development: a case study within Novartis.
    Heinzen M; Mettler S; Coradi A; Boutellier R
    Drug Discov Today; 2015 Mar; 20(3):301-5. PubMed ID: 25448754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physical layout of workspace: a driver for productivity in drug discovery.
    Ullman F; Boutellier R
    Drug Discov Today; 2008 May; 13(9-10):374-8. PubMed ID: 18468554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
    Federsel HJ
    Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Organizational effectiveness: a key to R&D productivity.
    Tollman P; Panier V; Dosik D; Biondi P; Cuss F
    Nat Rev Drug Discov; 2016 Jul; 15(7):441-2. PubMed ID: 27312725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring the efficiency of large pharmaceutical companies: an industry analysis.
    Gascón F; Lozano J; Ponte B; de la Fuente D
    Eur J Health Econ; 2017 Jun; 18(5):587-608. PubMed ID: 27344446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mergers and innovation in the pharmaceutical industry.
    Comanor WS; Scherer FM
    J Health Econ; 2013 Jan; 32(1):106-13. PubMed ID: 23220457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do large mergers increase or decrease the productivity of pharmaceutical R&D?
    Ringel MS; Choy MK
    Drug Discov Today; 2017 Dec; 22(12):1749-1753. PubMed ID: 28646641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A lesson from Japan: research and development efficiency is a key element of pharmaceutical industry consolidation process.
    Shimura H; Masuda S; Kimura H
    Drug Discov Ther; 2014 Feb; 8(1):57-63. PubMed ID: 24647159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving R&D productivity of pharmaceutical companies through public-private partnership: experiences from the Innovative Medicines Initiative.
    Laverty H; Gunn M; Goldman M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):545-8. PubMed ID: 23136843
    [No Abstract]   [Full Text] [Related]  

  • 12. The genetics of a pharma merger.
    Sanseau P; Chabot-Fletcher M; Browne MJ
    Drug Discov Today; 2009 Apr; 14(7-8):334-6. PubMed ID: 19121408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The paradox of scientific excellence and the search for productivity in pharmaceutical research and development.
    Grasela TH; Slusser R
    Clin Pharmacol Ther; 2014 May; 95(5):521-7. PubMed ID: 24458012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compound scale-up at the discovery-development interface.
    Nikitenko AA
    Curr Opin Drug Discov Devel; 2006 Nov; 9(6):729-40. PubMed ID: 17117683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research and development productivity map: visualization of industry status.
    Shimura H; Masuda S; Kimura H
    J Clin Pharm Ther; 2014 Apr; 39(2):175-80. PubMed ID: 24438433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Models for open innovation in the pharmaceutical industry.
    Schuhmacher A; Germann PG; Trill H; Gassmann O
    Drug Discov Today; 2013 Dec; 18(23-24):1133-7. PubMed ID: 23892183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development speed paradox: can increasing development speed reduce R&D productivity?
    Lendrem DW; Lendrem BC
    Drug Discov Today; 2014 Mar; 19(3):209-14. PubMed ID: 24051396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Workspaces that move people.
    Waber B; Magnolfi J; Lindsay G
    Harv Bus Rev; 2014 Oct; 92(10):68-77, 121. PubMed ID: 25509577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Torching the Haystack: modelling fast-fail strategies in drug development.
    Lendrem DW; Lendrem BC
    Drug Discov Today; 2013 Apr; 18(7-8):331-6. PubMed ID: 23246516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An assessment of R&D productivity in the pharmaceutical industry.
    Dimitri N
    Trends Pharmacol Sci; 2011 Dec; 32(12):683-5. PubMed ID: 22030299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.